Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial

…, R Decours, R Février, G Colin, S Abgrall… - The Lancet …, 2021 - thelancet.com
Background Elevated proinflammatory cytokines are associated with greater COVID-19 severity.
We aimed to assess safety and efficacy of sarilumab, an interleukin-6 receptor inhibitor, …

[HTML][HTML] Neurologic manifestations associated with COVID-19: a multicentre registry

…, A Wang, P Tattevin, T de Broucker, S Abgrall… - Clinical Microbiology …, 2021 - Elsevier
Objectives To provide an overview of the spectrum, characteristics and outcomes of neurologic
manifestations associated with severe acute respiratory syndrome coronavirus 2 (SARS-…

Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV

S Grabar, H Selinger-Leneman, S Abgrall, G Pialoux… - Aids, 2009 - journals.lww.com
Objective: To estimate the prevalence and characteristics of long-term nonprogressor (LTNP)
and HIV controller patients in a very large French cohort of HIV1-infected patients. Methods…

Impact of risk factors for specific causes of death in the first and subsequent years of antiretroviral therapy among HIV-infected patients

…, MJ Mugavero, C Lewden, S Abgrall… - Clinical Infectious …, 2014 - academic.oup.com
Background. Patterns of cause-specific mortality in individuals infected with human
immunodeficiency virus type 1 (HIV-1) are changing dramatically in the era of antiretroviral therapy (…

Incidence and risk factors for toxoplasmic encephalitis in human immunodeficiency virus-infected patients before and during the highly active antiretroviral therapy era

S Abgrall, C Rabaud, D Costagliola… - Clinical Infectious …, 2001 - academic.oup.com
The occurrence of toxoplasmic encephalitis (TE) was studied among 19,598 and 17,016
patients enrolled in the French Hospital Database on human immunodeficiency virus whose …

The incidence of AIDS-defining illnesses at a current CD4 count≥ 200 cells/µL in the post–combination antiretroviral therapy era

…, P Reiss, C Mussini, O Kirk, S Abgrall… - Clinical infectious …, 2013 - academic.oup.com
Background. Few studies consider the incidence of individual AIDS-defining illnesses (ADIs)
at higher CD4 counts, relevant on a population level for monitoring and resource allocation. …

Effect estimates in randomized trials and observational studies: comparing apples with apples

…, C Sabin, D Costagliola, S Abgrall… - American journal of …, 2019 - academic.oup.com
Abstract Effect estimates from randomized trials and observational studies might not be
directly comparable because of differences in study design, other than randomization, and in …

Tuberculosis-associated immune restoration syndrome in HIV-1-infected patients involves tuberculin-specific CD4 Th1 cells and KIR-negative γδ T cells

…, A Samri, C Parizot, M Lafaurie, S Abgrall… - The Journal of …, 2009 - journals.aai.org
Tuberculosis (TB)-associated immune restoration syndrome (IRS) is a frequent event (10 to
30%) in HIV-1-infected patients receiving antiretroviral treatment and is associated with an …

Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies

…, RJ Harris, JAC Sterne, S Abgrall… - Antiviral …, 2008 - journals.sagepub.com
Background In HIV type-1-infected patients starting highly active antiretroviral therapy (HAART),
the prognostic value of haemoglobin when starting HAART, and of changes in …

Cohort profile: French hospital database on HIV (FHDH-ANRS CO4)

…, S Grabar, L Lievre, S Abgrall… - International journal …, 2014 - academic.oup.com
The French Hospital Database on HIV (FHDH) is a hospital-based multicentre open cohort
with inclusions ongoing since 1989. The research objectives focus mainly on mid- and long-…